Seelos Therapeutics, Inc. (SEEL)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Seelos Therapeutics, Inc. (SEEL)
Company Performance

Current Price

as of Oct 16, 2024

$1.17

P/E Ratio

0.01

Market Cap

$743.68K

Description

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The company was founded by Raj Mehra in 1987 and is headquartered in New York, NY.

Metrics

Overview

  • HQNew York, NY
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerSEEL
  • Price$1.17-8.59%

Trading Information

  • Market Cap$0.74M
  • Float98.93%
  • Average Daily Volume (1m)18,094,566
  • Average Daily Volume (3m)7,550,318
  • EPS$211.31

Company

  • Revenue$2.01M
  • Rev Growth (1yr)11.90%
  • Net Income$1.71M
  • Gross Margin96.01%
  • EBITDA Margin-830.85%
  • EBITDA-$3.12M
  • EV$11.36M
  • EV/Revenue5.64
  • P/E0.01
  • P/S0.10
  • P/BN/A
Documents
SEC Filings
8-K (2024-10-15)
8-K (2024-10-07)
8-K (2024-09-26)
8-K (2024-09-25)
8-K (2024-09-24)
8-K (2024-09-03)
8-K (2024-08-08)
8-K (2024-07-26)
8-K (2024-07-16)
8-K (2024-07-12)
8-K (2024-06-05)
8-K (2024-05-21)
8-K (2024-05-16)
8-K (2024-05-14)
8-K (2024-05-03)
8-K (2024-03-28)
8-K (2024-03-19)
8-K (2024-01-30)
8-K (2024-01-22)
8-K (2024-01-10)
8-K (2023-12-01)
8-K (2023-11-30)
8-K (2023-11-28)
8-K (2023-11-24)
8-K (2023-11-03)
8-K (2023-10-02)
8-K (2023-09-25)
8-K (2023-09-20)
8-K (2023-09-14)
8-K (2023-06-29)
8-K (2023-05-26)
8-K (2023-05-19)
8-K (2023-03-24)
8-K (2023-03-14)
8-K (2023-03-10)
10-Q (2024-08-14)
10-Q (2024-05-14)
10-Q (2023-11-14)
10-Q (2023-08-11)
10-Q (2023-05-12)
10-K (2024-03-06)
10-K (2023-03-10)
Earnings Calls
Earnings Report 2017Q4
Earnings Report (2018-03-01)
Factset
Factset Business Description
Factset Street Account
Seelos Therapeutics retains Canaccord Genuity in connection with review of potential partnerships and collaborations ($0.18, 0.00) (2023-10-17T12:01:34Z)
Seelos Therapeutics reports Q3 EPS ($0.12) vs year-ago ($0.18) - 10-Q ($0.12, 0.00) (2023-11-14T22:29:37Z)
Seelos Therapeutics commences public offering through Titan Partners Group ($2.36, 0.00) (2023-11-28T21:09:36Z)
Seelos Therapeutics announces selection of SLS-002 (intranasal racemic ketamine) for inclusion in U.S. Dept. of Defense adaptive platform trial to evaluate potential treatments for PTSD ($0.13, 0.00) (2023-11-27T13:03:31Z)
Seelos Therapeutics announces 1-for-30 reverse stock split ($0.14, -0.03) (2023-11-24T15:55:08Z)
Seelos Therapeutics $5.6M share-and-warrant secondary priced at $1.32/unit through Titan Partners Group ($2.38, 0.00) (2023-11-29T02:30:45Z)
Insider transaction: Seelos Therapeutics CFO Michael Golembiewski discloses purchase of 83K shares - Form 4 ($1.38, 0.00) (2023-12-01T21:20:38Z)